On April 30, 2026, the U.S. Food and Drug Administration published a proposed rule to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List — formally concluding that there is no clinical need for outsourcing facilities to compound these molecules from bulk substances when the FDA-approved brands are commercially available. The proposal is open for public comment through June 29, 2026, and a final rule is expected later in the year.
The headlines have been confusing. Some say compounded GLP-1s are "banned"; others say "nothing has changed." Both are wrong. The accurate version is more granular — and important for patients trying to make a decision in 2026.
What actually changed on April 30.
The proposal applies to 503B outsourcing facilities — large-scale compounding pharmacies that produce non-patient-specific batches and distribute them broadly. Once the rule finalizes, 503B facilities will not be able to lawfully compound semaglutide, tirzepatide, or liraglutide from bulk drug substances unless a specific drug shortage is in effect.
The proposal does not by its terms eliminate 503A patient-specific compounding, the smaller-scale pharmacy model where a licensed pharmacist compounds a specific medication for a specific patient on a specific prescription. The 503A and 503B authorities operate under different sections of the Federal Food, Drug, and Cosmetic Act, and the April 30 proposal speaks to 503B exclusively. That said, the regulatory trend is clear: the FDA's posture toward broad compounding of FDA-approved GLP-1s — at either scale — is tightening, and the practical supply of compounded GLP-1 outside of brand has been narrowing throughout 2025–2026.
Where each molecule currently stands.
| Drug | Brand status | Shortage list? | 503B bulk compounding | 503A patient-specific |
|---|---|---|---|---|
| Semaglutide | FDA-approved (Ozempic, Wegovy, Rybelsus) | Removed (resolved 2025) | Proposed exclusion April 30, 2026 | Narrow lane only; physician-specific clinical need required |
| Tirzepatide | FDA-approved (Mounjaro, Zepbound) | Removed (resolved 2024) | Proposed exclusion April 30, 2026 | Narrow lane only; physician-specific clinical need required |
| Liraglutide | FDA-approved (Victoza, Saxenda) | Currently on shortage list | 503B compoundable while shortage persists; proposed exclusion when shortage resolves | Narrow lane only |
| Retatrutide | Not FDA-approved | N/A (no approved version exists) | No legal compounding lane — never qualified for the shortage exemption | Compounded retatrutide is not a legal product |
The retatrutide row is the one the peptide-clinic market keeps trying to blur. Retatrutide does not have an FDA-approved branded version, so it has no "shortage" to qualify for the section 506 compounding exemption. Compounded retatrutide does not occupy a legal lane in 2026 — it is sold as a "research compound" or in a regulatory gray-market that is unsafe to recommend to patients. We do not.
The three lanes a Limitless patient sees in 2026.
FDA-approved brand semaglutide or tirzepatide.
For most patients with a clinical indication for a GLP-1 in 2026, the right answer is the FDA-approved brand — Wegovy, Zepbound, Ozempic, or Mounjaro. Branded supply is now reliable. Insurance coverage is variable but improving. Manufacturer savings programs reduce out-of-pocket cost meaningfully for many patients. The brand pathway is the cleanest combination of safety, regulatory durability, and outcome data.
503A patient-specific compounded GLP-1.
503A patient-specific compounding remains a lane when there is a documented physician-specific clinical need that the FDA-approved product cannot meet — for example, a documented allergy or intolerance to an inactive ingredient in the branded product, or a need for a non-standard dose or concentration. This lane is intentionally narrow. It is not a discount lane; it is an indication lane. Limitless considers 503A-compounded semaglutide or tirzepatide only in the narrow case where (a) the FDA-approved product is not clinically appropriate for this patient, (b) a 503A-licensed partner pharmacy is in the loop with a documented formulation and COA, and (c) the clinical reasoning is in the chart.
"Cheap compounded GLP-1" telehealth.
The model that powered much of the 2023–2025 compounded-GLP-1 boom — broad, non-patient-specific 503B output marketed through telehealth platforms — is the model the FDA is closing. It is also the model where ingredient sourcing was most opaque, where dosing errors were most common, and where patient surveillance was thinnest. This is not a Limitless option, by design, regardless of what the final rule looks like.
What this means for current Limitless patients on GLP-1.
Nothing immediate. The Limitless GLP-1 protocol has not relied on 503B bulk compounding; we work with FDA-approved brand where indicated, and with 503A patient-specific compounding only on the narrow lane described above. For any patient currently on a compounded GLP-1 through Limitless, we will continue the protocol as written and notify you individually if any sourcing or formulation change becomes necessary as the rule finalizes.
What this means for prospective patients evaluating us against cheaper alternatives.
Some weight-loss telehealth services advertise compounded semaglutide or tirzepatide at price points well below the FDA-approved brand. The pricing is real. The regulatory durability is not. Many of those services will be repricing or rationing in the second half of 2026 as the 503B rule finalizes; some will exit the category. The Limitless pricing reflects FDA-approved sourcing for the default lane, physician-supervised lab-anchored care, and a model that does not depend on a contracting regulatory gray-zone to clear. We think that is the more honest place to start, even when it is not the cheapest.
- April 30, 2026: FDA published proposed rule to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list.
- June 29, 2026: Public comment period closes on the 503B exclusion proposal.
- July 23–24, 2026: PCAC meeting — separate docket; peptide-bulks review (see PCAC pre-vote summary). Not a GLP-1 vote, but a coordinated regulatory cadence.
- Late 2026 (anticipated): FDA final rule on the 503B GLP-1 exclusion is expected.
- Ongoing: Liraglutide injection remains on the shortage list and remains compoundable by 503B under the shortage exemption while that status holds.
What we do not say.
- "Compounded GLP-1 is banned." It is not — patient-specific 503A compounding remains lawful with proper indication. The 503B large-batch lane is the one being closed.
- "Brand and compounded GLP-1 are equivalent." Branded products carry the manufacturer's quality, post-marketing surveillance, and outcome data. 503A-compounded equivalents do not, even from a careful partner pharmacy.
- "Retatrutide is a legitimate option in 2026." It is not. It is an investigational compound with no approved version and no legal compounding lane.
- "The compounded GLP-1 telehealth model is going to recover." Even with shortage protections lapsing, the regulatory trajectory has been consistent for two years: the floor under broad, low-cost compounded GLP-1 is being lifted.
The bottom line.
The April 30 proposal is the largest single shift in compounded GLP-1 regulation since the 2022–2024 shortage cycle. For Limitless patients, the practical effect is small — because the practice never built its GLP-1 program on 503B bulk compounding to begin with. For patients deciding between Limitless and a cheap-compounded-GLP-1 telehealth service in 2026, the proposal is the clearest signal yet that the cheaper lane is not durable. Brand for the default indication. 503A patient-specific only where there is a real clinical reason. Surveillance and labs throughout. That is the answer that does not need to be rewritten when the rule finalizes.